ÁñÁ«ÊÓƵ Network Open
Original Investigation
Oncology
March 20, 2024
Rana R.ÌýMcKay, MD; Tyler J.ÌýNelson, BS; Meghana S.ÌýPagadala, BS; Craig C.ÌýTeerlink, PhD; Anthony Gao, BS; Alex K.ÌýBryant, MD, MAS; Fatai Y.ÌýAgiri, BS; Kripa Guram, MD; Reid F.ÌýThompson, MD, PhD; Kathryn M.ÌýPridgen, MA; Tyler M.ÌýSeibert, MD, PhD; Kyung Min Lee, PhD; Hannah Carter, PhD; Julie A.ÌýLynch, PhD; Richard L.ÌýHauger, MD; Brent S.ÌýRose, MD
open access
ÁñÁ«ÊÓƵ Netw Open. 2024; 7(3):e242976. 10.1001/jamanetworkopen.2024.2976
This cohort study analyzes the association of HSD3B1 status with prostate cancer outcomes among patients in the Veterans Affairs Health System in the US.
JAMA
Original Investigation
April 6, 2024
Richard M.ÌýMartin, BM, BS, PhD; Emma L.ÌýTurner, PhD; Grace J.ÌýYoung, MSc; Chris Metcalfe, PhD; Eleanor I.ÌýWalsh, MSc; J. Athene Lane, PhD; Jonathan A. C.ÌýSterne, PhD; Sian Noble, PhD; Peter Holding, MSc; Yoav Ben-Shlomo, MBBS, PhD; Naomi J.ÌýWilliams, PhD; Nora Pashayan, MD, PhD; Mai Ngoc Bui, PhD; Peter C.ÌýAlbertsen, MD; Tyler M.ÌýSeibert, MD, PhD; Anthony L.ÌýZietman, MD; Jon Oxley, MD; Jan Adolfsson, MD; Malcolm D.ÌýMason, MD; George Davey Smith, DSc; David E.ÌýNeal, MD; Freddie C.ÌýHamdy, MD; Jenny L.ÌýDonovan, PhD; CAP Trial Group
is active quiz
has multimedia
JAMA. 2024; 331(17):1460-1470. 10.1001/jama.2024.4011
This secondary analysis of a randomized clinical trial assesses whether screening for prostate-specific antigen reduces prostate cancer mortality at 15-year follow-up.
JAMA Otolaryngology–Head & Neck Surgery
Comment & Response
November 16, 2023
¸é²â²¹²ÔÌý³§³Ü²Ô,Ìý±Ê³ó¶Ù; Tyler M.ÌýSeibert, MD, PhD; Lee-Jen Wei, PhD
JAMA Otolaryngol Head Neck Surg. 2023; 150(1):84-85. 10.1001/jamaoto.2023.3634